Introduction {#s0001}
============

Coronavirinae family is made up of four genera based on their genetic material, including Alpha, Beta, Gamma and Delta coronavirus genus. The coronavirus family is a positive-stranded RNA virus, which mainly causes respiratory and central nervous system disease (Perlman & Netland, [@CIT0048]). Human coronaviruses namely HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1 are responsible for mild respiratory diseases (Owusu et al., [@CIT0043]). The SARS-CoV outbreak in 2002 demonstrated that coronaviruses would cross the barrier to species and emerge as highly pathogenic viruses (Perlman, [@CIT0047]). The disease caused by SARS-CoV-2 is called COVID-19. The coronavirus has been named SARS-CoV-2 (Gorbalenya et al., [@CIT0028]), because the RNA genome is about 82% identical to the SARS coronavirus (SARS-CoV); both viruses belong to the genus beta-coronavirus (Wu et al., [@CIT0057]; Zhou et al., [@CIT0063]). The novel COVID-2019 was first reported in Wuhan, China in December 2019. The outbreak has been rapidly spread all over the world. More than 200 countries were affected by this COVID-19. The world health Organization **(WHO)** announced on 11^th^ march 2020 that the COVID-19 as pandemic disease. Currently, more than 4,310,786 number (as on 12^th^ May 2020) of people were infected with COVID-19 which is increasing by approximately 100000+ cases per day and more than 290,455 people have died. Unfortunately, to date, there is no medication or vaccine approved by the World Health Organization **(WHO)**, the Centers for Disease Control and Prevention **(CDC)**, and the **FDA** for the effective treatment of COVID-19 (CDC, [@CIT0012] WHO, [@CIT0056]).

Many drugs have been tried recently in the treatment of COVID-19 due to the situation of "public-health emergency", that includes antimalarial drugs (Chloroquine and its derivative Hydroxychloroquine) (Colson et al., [@CIT0014]; Gao et al., [@CIT0026]; Wang et al., [@CIT0055]; Yao et al., [@CIT0059]) antiviral drugs (HIV Protease Inhibitors i.e. Lopinavir and Ritonavir) (Chu et al., [@CIT0013]; Yao et al., [@CIT0059]), investigational nucleoside analogue (Remdesivir (GS-5734)) (Agostini et al., [@CIT0004]; Wang et al., [@CIT0055]) and investigational RNA-dependent RNA polymerase inhibitor (Favipiravir) (Beijing Chao Yang Hospital, [@CIT0009]; Peking University First Hospital, [@CIT0046]; Wang et al., [@CIT0055]). Some Adjunctive therapeutic drugs are also used for the treatment of COVID-19, which includes macrolide antibacterial drug (Azithromycin) (Amsden, [@CIT0006]; Beigelman et al., [@CIT0008]; Gautret et al., 2020), Interleukin-6 (IL-6) Receptor-Inhibiting Monoclonal Antibody (Tocilizumab, Sarilumab) (Assistance Publique -- Hopitaux de Paris, [@CIT0007]; Xu et al., [@CIT0058]; Zhou et al., [@CIT0063]) and Investigational Humanized Monoclonal Antibody to the Chemokine Receptor CCR5 (Leronlimab) (CytoDyn, [@CIT0015]; Zhou et al., [@CIT0063]). The detailed outcomes of the clinical trials are still awaited. However, among all these reported drugs Chloroquine and Hydroxychloroquine were used/being used widely for the treatment of COVID-19.

Many research institutes as well as pharmaceutical companies are working to identify potential candidate against SARS-CoV-2 worldwide. Some researcher reported that Chloroquine has the potential to treat COVID-19 with clinical study as well as in silico study (Adeoye et al., [@CIT0003]) Boopathi et al., [@CIT0011]; Gao et al., [@CIT0026]). Department of Pathology, Vanderbilt University Medical Center, USA reported that antiviral Remdesivir (GS-5734) can treat SARS-CoV-2 (Agostini et al., [@CIT0004]). The investigation of COVID-19 with Plasma therapy and its clinical trials are being conducted to evaluate the use of COVID-19 to treat patients with severe or immediately life-threatening COVID-19 infections (Duan et al., [@CIT0018]). Hasan et al. reviewed the ongoing challenges and future prospects for the development of potential drugs to promote targeting specific activities of the CoV (Hasan et al., [@CIT0031]). Some research groups are also working in the field of computational approach to find a solution for COVID-19. Khan et al. worked on a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-Oribose methyltransferase and proposed that Raltegravir, Paritaprevir, Bictegravir and Dolutegravir are excellent lead candidates for these crucial proteins and they could become potential therapeutic drugs against SARS-CoV-2 (Khan et al., [@CIT0035]). 3,4 Dihydropyrimidone class molecule identified as a drug candidate against 2019-nCoV N-protein (N terminal domain) (Sarma et al., [@CIT0050]). Enayatkhani et al. worked on reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19 and conclude with NOM-TLR4 and NOM-HLA-A11:01 docked model (Enayatkhani et al., [@CIT0023]). Elfiky et al. suggested guanosine derivatives (Guanosine triphosphate (GTP), Uridine triphosphate (UTP), IDX-184 (GTP derivative), sofosbuvir (UTP derivative), ribavirin (wide acting antiviral drug) can be the potential candidate against COVID-19 (Elfiky & Azzam, [@CIT0021]). Zhou et al. and Joshi et al. reported the network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2 (Joshi et al., [@CIT0034]; Zhou et al., [@CIT0063]). Zhang et al. from Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Lübeck, Germany designed the improved α-ketoamide inhibitors for the inhibition of SARS-CoV-2 (Zhang et al., [@CIT0062]). Yogi Vemana University, India, Government Medical College, Anantapur, India and ICAR-National Rice Research Institute, India collaboratively worked on In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel (Gupta et al., [@CIT0029]). A few in silico research has also been done by considering FDA approved drugs and concludes with Lopinavir (Pant et al., [@CIT0044]), Setrobuvir (Elfiky, [@CIT0019]), Saquinavir (Al-Khafaji et al., [@CIT0005]) Remdesivir, Saquinavir, Darunavir, (Khan et al., [@CIT0035]) and Disulfiram (Lobo-Galo et al., [@CIT0040]) which have better interactions with SARS CoV-2. Some compounds like Crocin, Digitoxigenin, b-Eudesmol, (Aanouz et al., [@CIT0001]) Andrographolide, (Enmozhi et al., 2020) phytoestrogens (Diadiazin, Genistein, Formontein and Biochanin A), (Elfiky, [@CIT0020]) phytochemicals (hypericin, cyanidin 3-glucoside, baicalin, glabridin, and α-ketoamide-11r), (Islam et al., [@CIT0032]) Resveratrol, (Wahedi et al., [@CIT0054]) Rutin, (Das et al., [@CIT0017]) Ammoides verticillata, (Abdelli et al., [@CIT0002]) alkaloids (10--Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one) (Gyebi et al., [@CIT0030]) also reported as a better candidate against COVID-19. Umesh et al. Worked on Indian spices to study structure based interaction with COVID-19 and conclude with three compounds Carnosol, Arjunglucoside-I and Rosmanol (Umesh et al., [@CIT0053]). Sinha et al. evaluated different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets (Sinha et al., [@CIT0052]).

As Hydroxychloroquine is the derivative of Chloroquine and shows better inhibition in comparison to Chloroquine against SARS CoV-2 (Pastick et al., [@CIT0045]; Yao et al., [@CIT0059]), the current study is emphasized on the derivatives of Chloroquine against COVID-19. A set of 18 molecules based on Chloroquine scaffold ([Scheme 1](#SCH0001){ref-type="scheme"}) are designed and optimized computationally by using Schrodinger software. These molecules were designed by substituting different groups (like, methyl (CH3), hydroxyl group (OH), NO2, Amino group (NH2), halogens (F, Cl and Br) and ring aromatic (benzene, phenol)) at the position of R1 and R2 ([Scheme 1](#SCH0001){ref-type="scheme"}). These groups were considered due to its potential to interact with the amino acids (like 'hydroxyl group, methyl and amine can interact with the amino acid through H-bond', 'halogens; Cl, Br, F can interact through halogen bonding', 'NO2 can show H-bond as well as salt bridges' and 'ring aromatic compounds can show pi-pi and pi-cation interactions. In addition to pi-pi and pi-cation interactions the phenol can also show H-bonding due to OH group') (Rawel et al., [@CIT0049]; Zavodszky & Kuhn, [@CIT0061]). The generated pharmacophore model can efficiently explain the essential structural features present in the molecules having the potency to interact with the target protein. Molecular docking, MM/GBSA study, ADME property and MD simulation analysis have been employed to study and identify the candidate having better interactions and binding affinity with the SARS-CoV-2.

![Chemical structure of Chloroquine scaffolds. \[\]](TBSD_A_1772111_SCH0001_B){#SCH0001}

Methodology {#s0002}
===========

Molecular simulation studies were performed by using Maestro 12.3 module (Schrodinger Release 2020-1, [@CIT0051]). All the 18 designed molecules (including chloroquine and hydroxychloroquine) and protein (**6LU7**) (Jin et al., [@CIT0033]; Muralidharan et al., [@CIT0042]; Elmezayen et al., [@CIT0022]; Kumar et al., [@CIT0038]) were optimized and followed the methodology of pharmacophore hypothesis, molecular docking, MM-GBSA study, ADME property analysis and molecular dynamics (MD) simulations as per the previous reports (Beura & Chetti, [@CIT0010]; Ganjoo et al., [@CIT0025]) and detailed methodologies are given in supporting information. The detailed working methodology flowchart is shown in [Scheme 2](#SCH0002){ref-type="scheme"}.

![Working methodology.](TBSD_A_1772111_SCH0002_C){#SCH0002}

For the validation of theoretical results, a set of different PDB_IDs i.e. 5REB (Fearon et al., [@CIT0024]), 6W02 (Michalska et al., [@CIT0041]) were downloaded from protein data bank and re-docking of the self ligand with the protein was performed by using 'Ligand Docking' module with extra precision (XP) mode. RMSE values were calculated between crystal and re-dock pose by using the 'superimpose' module. RMSD value generated by re-docking the native ligands in the active site of the respective protein was 1.33 Å, and 1.29 Å. As the RMSD values are less than X-ray resolution of the corresponding protein which is 1.68 Å, and 1.5 Å. It indicates that the generated model has a good correlation with the experimental X-ray crystal structures ([Figure 1](#F0001){ref-type="fig"}).

![Superimpose of the self-docked ligand with native ligand in the protein grid (a) 5REB and (b) 6W02.](TBSD_A_1772111_F0001_C){#F0001}

Result and discussion {#s0003}
=====================

Pharmacophore model {#s0004}
-------------------

A total of 20 pharmacophore hypothesis models ([Table 1](#t0001){ref-type="table"}) were generated by using the 'phase module.' The hypotheses have consisted of all active match molecules. There were 2 types of different models generated like DHHHRR (model 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10) and DHHRR (model 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20). Out of 20 models, DHHHRR_1 was considered as the best model as this six featured models shows the best PhaseHypoScore (1.383), Survival Score (6.392) and good BEDROC score (0.999). Pharmacophore hypothesis model DHHHRR_1 consists of one H-bond donor (blue color), three hydrophobic sites (green color) and two aromatic rings (orange color), shown in [Figure 2(a)](#F0002){ref-type="fig"} (also shown the position of features concerning each other in [Figure 2(a)](#F0002){ref-type="fig"}). DHHHRR_1 model shows proper fit with all designed ligands. For example; Hydroxychloroquine and **CQD14** shows a proper fit with the best pharmacophore model DHHHRR_1 ([Figure 2(b)](#F0002){ref-type="fig"}) which indicates all the optimized Chloroquine derivatives are having nearly similar orientations.

![(a) Arrangement of individual features in a fixed distance (in Å) of pharmacophore hypothesis model DHHHRR_1 for Chloroquine derivatives. (b) Mapping of molecules on pharmacophore hypothesis model DHHHRR_1.](TBSD_A_1772111_F0002_C){#F0002}

###### 

Phase generated pharmacophore hypothesis models for chloroquine derivatives **(CQD)**.

  S. No.   Title       BEDROC Score   Survival Score   PhaseHypoScore
  -------- ----------- -------------- ---------------- ----------------
  1        DHHHRR_1    0.999          6.392            1.383
  2        DHHHRR_2    1              6.374            1.382
  3        DHHHRR_3    1              6.372            1.382
  4        DHHHRR_4    0.998          6.364            1.380
  5        DHHHRR_5    1              6.362            1.382
  6        DHHHRR_6    0.995          6.341            1.376
  7        DHHHRR_7    1              6.334            1.380
  8        DHHHRR_8    1              6.331            1.380
  9        DHHHRR_9    1              6.299            1.378
  10       DHHHRR_10   0.999          6.288            1.376
  11       DHHRR_1     1              5.869            1.352
  12       DHHRR_2     0.995          5.853            1.346
  13       DHHRR_3     1              5.814            1.349
  14       DHHRR_4     1              5.804            1.348
  15       DHHRR_5     1              5.792            1.348
  16       DHHRR_6     0.994          5.768            1.341
  17       DHHRR_7     0.996          5.765            1.342
  18       DHHRR_8     0.987          5.765            1.333
  19       DHHRR_9     1              5.759            1.346
  20       DHHRR_10    1              5.744            1.345

The Pharmacophore models were generated to study the maximum number of structural features present in the designed molecules. The ligand-receptor interactions depends upon these structural features present in the ligand like, H-bond acceptor (A, red color ball), H-bond donor (D, blue color ball), Aromatic rings (R, orange color ring) and Hydrophobic region (H, green color ball) ([Figure 3](#F0003){ref-type="fig"}). The selected molecules **CQD-15**, **CQD-14** and **CQD-16** shows 13, 12 and 13 number of structural features whereas Chloroquine and Hydroxychloroquine shows 9 and 10 number of structural features. It indicates that the selected molecules **CQD-15**, **CQD-14** and **CQD-16**, have the potential to interact with the enzyme ([Figure 3](#F0003){ref-type="fig"} and Figure S1).

![Pharmacophre model generated structural features present in the ligands (**Hydroxychloroquine** and **CQD15**).](TBSD_A_1772111_F0003_C){#F0003}

Molecular docking {#s0005}
-----------------

The generated active site of SARS-CoV-2 main protease **(PDB ID: 6LU7)** is occupied by charged amino acids (ARG-298, LYS-102, ASP-153 and ASP-295), polar amino acids (THR-111, GLN-110, GLN-127, THR-292, ASN-151 and SER-158) and hydrophobic amino acid (ILE-152, TYR-154, PRO-9, PHE-8, PHE-112, PHE-294, VAL-104, VAL-297 and ILE-106) residue. To ensure the excavation of the best candidates, molecular interaction study was performed through ligand docking into the active site of the SARS-CoV-2. The designed 18 molecules were visually inspected based on the docking score, ligand-receptor interactions, H-bonding, hydrophobic potential, electrostatic rewards and rewards for the ligand of low molecular weight. This deep study concludes with 3 best molecules i.e. **CQD15**, **CQD14** and **CQD16** and are showing docking scores of -6.17, −5.14 and -4.19 respectively ([Table 2](#t0002){ref-type="table"}). **CQD15** shows three H-bonds with two polar amino acids (THR-111 and GLN-110) and one charged amino acid (ASP-153), two H-bonds due to the H-bond donor group and one due to H-bond acceptor site present in the ligand. Additionally, **CQD15** shows one pi-pi interaction with hydrophobic amino acid (PHE-8) ([Figure 4](#F0004){ref-type="fig"}). **CQD14** shows 2 H-bond interactions due to two H-bond donor groups present in the ligand along with one pi-pi interaction. The H-bond interactions take place with one polar amino acid (THR-111) and one charged amino acid (GLN-110) present in the active site ([Figure 4](#F0004){ref-type="fig"}). **CQD16** shows similar interactions like **CQD15** and additionally, it shows one pi-pi interaction with hydrophobic PHE-294 amino acid ([Figure 4](#F0004){ref-type="fig"}). All 3 new ligands showing a good range of solvent exposures ([Figure 4](#F0004){ref-type="fig"}) and the docked pose shows the best fit of the ligand in the active site cavity of the enzyme ([Figure 5](#F0005){ref-type="fig"}).

![Ligand-receptor interaction diagram of chloroquine derivative molecules (**CQD14**, **CQD15** and **CQD16**) with the SARS-CoV-2 **(PDB ID: 6LU7)**.](TBSD_A_1772111_F0004_C){#F0004}

![Molecular docking pose of Chloroquine, Hydroxychloroquine, **CQD14**, **CQD15** and **CQD16** with the SARS-CoV-2 **(PDB ID: 6LU7)**. (a) Complete image of ligands binding with the protein (b) Magnified image of ligands binding at the active site.](TBSD_A_1772111_F0005_C){#F0005}

###### 

Docking score and functional parameters of all 18 molecules including Chloroquine and Hydroxychloroquine with SARS-CoV-2 main protease (PDB ID: 6LU7).

  S. No.   Ligand               DockScore   LipophilicEvdW   PhobEnHB   HBond   Electro   LowMW
  -------- -------------------- ----------- ---------------- ---------- ------- --------- -------
  1        CQD15                −6.17       −2.24            −1.5       −1.87   −1.1      −0.12
  2        CQD14                −5.14       −1.93            −1.5       −1.35   −0.77     −0.13
  3        CQD16                −4.19       −2.78            0          −1.11   −0.63     −0.12
  4        CQD6                 −4.15       −2.57            0          −1.15   −0.63     −0.38
  5        CQD5                 −3.92       −1.45            −1.5       −0.7    −0.42     −0.28
  6        Hydroxychloroquine   −3.48       −2.38            0          −1.28   −0.48     −0.38
  7        CQD13                −3.44       −2.68            0          −1.15   −0.6      −0.18
  8        CQD12                −3.41       −2.49            0          −1.25   −0.47     −0.17
  9        CQD9                 −3.39       −3.26            0          −0.04   −0.14     −0.37
  10       CQD10                −3.3        −2.64            0          −0.52   −0.21     −0.38
  11       Chloroquine          −3.27       −2.86            0          −0.34   −0.15     −0.43
  12       CQD7                 −3.08       −3.36            0          0       −0.14     −0.17
  13       CQD4                 −3.04       −2.46            0          −1.68   −0.62     −0.38
  14       CQD1                 −3.01       −2.78            0          −0.45   −0.14     −0.17
  15       CQD8                 −2.93       −3.24            0          −0.02   −0.12     −0.32
  16       CQD2                 −2.9        −2.84            0          0       −0.14     −0.32
  17       CQD11                −2.78       −2.83            0          0       −0.26     −0.18
  18       CQD3                 −2.73       −2.75            0          0       −0.24     −0.37

LipophilicEvdW: Lipophilic term derived from hydrophobic grid potential and fraction of the total protein-ligand vdW energy

PhobEnHB: Reward for hydrophobicallypacked H-bond

HBond: ChemScore H-bond pair term

Electro: Electrostatic rewards

LowMW: Reward for ligands with low

The comparative analysis of selected molecules (**CQD15**, **CQD14** and **CQD16**) with Chloroquine and Hydroxychloroquine were studied. Chloroquine and Hydroxychloroquine are showing a docking score of -3.27 and -3.48 respectively ([Table 2](#t0002){ref-type="table"}). Chloroquine shows one pi-pi stacking with hydrophobic region (PHE-294) along with a good range of solvent exposure where as Hydroxychloroquine shows two H-bond interactions, one is due to H-bond acceptor and another is due to H-bond donor group present in the active site of SARS-CoV-2. The selected molecules (**CQD15**, **CQD14** and **CQD16**) were showing better docking scores (-6.17, −5.14 and -4.19 respectively) as well as better ligand-receptor interactions in comparison to chloroquine and hydroxychloroquine ([Figure 6](#F0006){ref-type="fig"}).

![Ligand-receptor interaction diagram of chloroquine and hydroxychloroquine with the SARS-CoV-2(PDB ID: 6LU7).](TBSD_A_1772111_F0006_C){#F0006}

Further, the designed ligands were also docked with coronavirus SARS Spike Glycoprotein - human ACE2 complex (PDB ID: 6CS2) (Kirchdoerfer et al., [@CIT0037]) to study the impact of ligands on SARS Spike Glycoprotein - human ACE2 complex. The docking study of "ligand and SARS Spike Glycoprotein - human ACE2 complex" shows similar result like "ligand and COVID-19 main protease". The ligands **CQD-15**, **CQD-14** and **CQD-16** showing docking score of -6.47, −5.48, and 5.35 respectably where as Choloroquine and Hydroxychloroquine shows -3.56 and -3.6 respectively ([Table 3](#t0003){ref-type="table"}). The detailed interaction diagrams are shown in Figure S2a--S2e. Docking study is also performed with SARS-CoV-2 main protease (PDB ID: 7BUY) (Zhao et al., [@CIT0066]) to validate the ligand-main protease interactions. The study also concludes with same ligands **CQD-16**, **CQD-15** and **CQD-14** which shows better docking score and ligand-receptor interactions in comparison to Chloroquine and Hydroxychloroquine which follows the trend of ligand-6LU7 docking study. The detailed interactions and docking score are shown in Figure S3a--S3e and Table S1 respectively.

###### 

Docking score and functional parameters of all 18 molecules including Chloroquine and Hydroxychloroquine with coronavirus SARS Spike Glycoprotein - human ACE2 complex (PDB ID: 6CS2).

  Ligand               DockScore   LipophilicEvdW   PhobEnHB   HBond   Electro   LowMW
  -------------------- ----------- ---------------- ---------- ------- --------- -------
  CQD-15               −6.47       −3.77            −1.37      −1.25   −0.55     −0.12
  CQD-14               −5.48       −3.74            −1.5       −1.28   −0.38     −0.13
  CQD-16               −5.35       −3.32            −1.5       −2.2    −0.81     −0.12
  CQD-11               −5.33       −4.56            −0.75      −0.7    −0.38     −0.18
  CQD-12               −4.91       −3.21            −1.5       −0.94   −0.44     −0.17
  CQD-13               −4.88       −3.93            0          −1.2    −0.39     −0.18
  CQD-6                −4.78       −2.79            −1.5       −0.63   −0.34     −0.38
  CQD-7                −4.68       −2.69            −1.5       −0.7    −0.22     −0.17
  CQD-5                −4.44       −3.51            −0.75      −0.7    −0.49     −0.28
  CQD-4                −4.06       −3.38            0          −0.7    −0.41     −0.38
  CQD-9                −3.9        −3.38            0          −0.65   −0.32     −0.37
  CQD-10               −3.7        −3.44            0          −0.11   −0.25     −0.38
  CQD-2                −3.6        −3.53            0          0       −0.14     −0.32
  Hydroxychloroquine   −3.6        −3.28            0          0       −0.19     −0.38
  Chloroquine          −3.56       −3.48            0          0       −0.16     −0.43
  CQD-1                −3.54       −3.62            0          0       −0.07     −0.17
  CQD-3                −3.52       −3.62            0          0       −0.14     −0.37
  CQD-8                −3.51       −3.81            0          0       −0.05     −0.32

MM-GBSA study {#s0006}
-------------

All 18 molecules were subjected to ligand-receptor binding energy, MM-GBSA analysis. The MM-GBSA analysis computed the binding free energy of docked ligand-receptor complex which confirms the stability of the ligand after binding to the active site of the enzyme. The generated 'MM-GBSA_Dg_Bind' energy by using the MM-GBSA module shows the energy difference between prime energy (optimized ligand-receptor complex) and the combined energy of optimized free ligand and optimized free receptor. The MM-GBSA_dG_Bind energies for all 18 compounds are shown in [Table 4](#t0004){ref-type="table"}. MM-GBSA study concludes that all the molecules except **CQD1** and **CQD5** shows better binding energy in comparison to Choloroquine and Hydroxychloroquine.

###### 

MM-GBSA_dG_Bindvalues of 18 molecules in (kcal/mol) obtained through MM-GBSA analysis.

  Ligand               r_psp_MMGBSA_dG_Bind
  -------------------- ----------------------
  CQD15                −47.74711519
  CQD14                −58.40628355
  CQD16                −41.70415476
  CQD6                 −51.56851776
  CQD5                 −39.24253856
  Hydroxychloroquine   −40.34126469
  CQD13                −52.76079182
  CQD12                −49.54062105
  CQD9                 −53.07817314
  CQD10                −43.20765873
  Chloroquine          −40.46204749
  CQD7                 −55.4049401
  CQD4                 −58.3743558
  CQD1                 −32.47031282
  CQD8                 −52.27239411
  CQD2                 −51.74337235
  CQD11                −51.76783519
  CQD3                 −48.48654391

ADME analysis {#s0007}
-------------

The drug-likeness properties of the molecules studied by using well-known ADME analysis i.e. Absorption (A), Distribution (D), Metabolism (M) and Excretion (E) which explains the disposition of pharmaceutical compound inside an organism and therefore, influences the pharmacological activity of it. The screening was performed based on a violation of 'Lipinski's rule of five', **QPPCaco** and **QPlogS**. In the ADME property analysis out of 18 molecules, 3 were showing violation of 'Lipinski's rule of five' and (**QPlogS**) (shown in the bold in [Table 5](#t0005){ref-type="table"}) whereas remaining 15 molecules were following the standard parameters. All the molecules show percentage of oral absorption more than 70%. ADME property analysis concludes that all molecules except CQD1, CQD7 and CQD11 show drug-likeness properties.

###### 

ADME properties of all 18 ligands to determine their 'drug-likeness'.

  Ligand                mol_MW        donorHB   accptHB   QPlogPo/w   RuleOfFive   QPlogS       %Human Oral Absorption
  --------------------- ------------- --------- --------- ----------- ------------ ------------ ------------------------
  CQD15                 413.946       3         6.45      4.094       0            −4.705       91.032
  CQD14                 411.973       2         4.75      4.998       0            −4.7         100
  CQD13                 396.962       3         5         4.313       0            −3.387       92.144
  CQD12                 397.947       2         5.7       4.235       0            −3.367       100
  **CQD11**             **395.974**   **1**     **4**     **5.569**   **1**        **−4.44**    **100**
  CQD10                 334.891       3         5         2.496       0            −0.975       78.096
  CQD9                  337.867       1         4         4.661       0            −4.601       100
  CQD8                  354.322       1         4         4.991       0            −4.997       100
  **CQD7**              **398.773**   **1**     **4**     **5.066**   **1**        **−5.083**   **100**
  CQD6                  335.876       2         5.7       3.352       0            −3.13        95.059
  CQD5                  364.874       1         6         3.505       0            −3.524       92.172
  CQD4                  334.891       3         5         2.968       0            −2.604       79.338
  CQD3                  337.867       1         4         4.777       0            −4.824       100
  CQD2                  354.322       1         4         4.983       0            −4.944       100
  **CQD1**              **398.773**   **1**     **4**     **5.047**   **1**        **−4.798**   **100**
  Hydroxy-chloroquine   335.876       2         5.7       3.329       0            −3.335       93.491
  Chloroquine           319.876       1         4         4.559       0            −4.582       100
  CQD16                 412.961       4         5.75      3.619       0            −3.619       76.602

Molecular dynamics simulations {#s0008}
==============================

Protein RMSD {#s0009}
------------

MD simulations were performed to study the physical movements of atoms & molecules and the dynamic evolution for the best complex (**6LU7-CQD15**). The RMSD is a quantitative parameter to estimate the stability of the protein system ([Figure 7](#F0007){ref-type="fig"}). The protein RMSD trajectory of SARS-CoV-2 (**6LU7**) shows a fluctuation up to 5 ns simulation time then gradually tends to equilibrium ([Figure 7](#F0007){ref-type="fig"}). The RMSD average value of SARS-CoV-2 (**6LU7)** after reaching equilibrium was 1.6 Å ([Figure 7](#F0007){ref-type="fig"}) as for the small globular protein the deviation within 1-3 Å is acceptable. Based on the stability, **6LU7-CQD15** was considered for further study like Protein-Ligand contact study (Histograms and Graph).

![The Protein RMSD trajectory of the **(CQD15**-**6LU7)** complex during the 100 ns simulation.](TBSD_A_1772111_F0007_C){#F0007}

Ligand properties {#s0010}
-----------------

Ligand property study includes Ligand RMSD, Radius of Gyration (rGyr), Molecular Surface Area (MolSA), Solvent Accessible Surface Area (SASA) and Polar Surface Area (PSA). The root mean squre deviation (RMSD) of the ligand fluctuates up to 40 ns simulation and then gradually comes to equilibrium. The ligand is showing range of RMSD around 1 to 3 Å and the equilibrium around 2.5 Å ([Figure 8](#F0008){ref-type="fig"}). The rGyr is the radial distance to a point which would have a moment of inertia the same as the body's (ligand) actual distribution of mass, if the total mass of the body (ligand) were concentrated. rGyr of the ligand also showing a heavy fluctuate up to 65 ns simulation and then gradually comes to equilibrium. The ligand is showing range of rGyr around 4 to 6.4 Å and the equilibrium around 5.5 Å ([Figure 8](#F0008){ref-type="fig"}). MolSA is surface calculation with 1.4 Å probe radius. This value is equivalent to a van der Waals surface area. The MolSA of the ligand is constant throughout the simulation but there is some fluctuation in 42 ns to 65 ns simulation period. The ligand is showing range of MolSA around 360 to 400 Å^2^ and the equilibrium around 400 Å^2^ ([Figure 8](#F0008){ref-type="fig"}). SASA is surface area of a molecule accessible by a water molecule. SASA of the ligand also showing a heavy fluctuate up to 23 ns simulation and then gradually comes to equilibrium. The ligand is showing range of SASA around 300 to 600 Å^2^ and the equilibrium around 300 Å^2^ ([Figure 8](#F0008){ref-type="fig"}). PSA is solvent accessible surface area in a molecule contributed only by oxygen and nitrogen atoms. The PSA of the ligand is constant throughout the simulation but there is some fluctuation in 41 ns to 68 ns simulation period. The ligand is showing range of PSA around 80 to 120 Å^2^ and the equilibrium around 120 Å^2^ ([Figure 8](#F0008){ref-type="fig"}). All the ligand properties are showing some fluctuation in the initial simulation period or intermediate simulation period but gradually come to equilibrium at the end of the simulation which conforms that the stability of the ligand in the active site of the protein.

![The ligand property trajectory of the **(CQD15-6LU7)** complex during the 100 ns simulation.](TBSD_A_1772111_F0008_C){#F0008}

Protein-ligand contacts {#s0011}
-----------------------

The protein-ligand contacts of the stable ligand-receptor complex (**CQD15-6LU7)** was studied by using the protein-ligand contact histograms ([Figure 9](#F0009){ref-type="fig"}) (Dariya & Nagaraju, [@CIT0016]). Protein-ligand interactions (or 'contacts') are categorized into four types: *hydrogen honds*, *hydrophobic*, *ionic* and *water bridge*. Hydrogen bonds play a significant role in ligand binding. Consideration of hydrogen-bonding properties for drug design is important because of their strong influence on drug specificity, metabolization and adsorption. Hydrogen bonds between a protein and a ligand can be further broken down into four sub-types: backbone acceptor, backbone donor, side-chain acceptor and side-chain donor. The geometric criteria for protein-ligand hydrogen bond is of 2.5 Å between the donor and acceptor atoms (D---H···A), a donor angle of ≥120° between the donor-hydrogen-acceptor atoms (D---H···A) and an acceptor angle of ≥90° between the hydrogen-acceptor-bonded_atom (H···A---X). The histogram shows the active site amino acids (mainly GLN-107, GLN-110, THR-111, ASN-151, ASP-153, TYR-154, ASP-295) interacting through hydrogen bonding ([Figure 9](#F0009){ref-type="fig"}). *Hydrophobic* contacts fall into three subtypes like π-cation, π-π and other non-specific interactions. These types of interactions involve a hydrophobic amino acid and an aromatic or aliphatic group on the ligand. Some hydrophobic amino acids like VAL-104, ILE-106, TYR-154, ILE-249, PRO-252, PHE-294 and VAL-297 showing hydrophobic interactions with the ligand ([Figure 9](#F0009){ref-type="fig"}). *Ionicinteractions* or polar interactions, are between two oppositely charged atoms that are within 3.7 Å of each other and do not involve a hydrogen bond. All *ionic interactions* are broken down into two subtypes: those mediated by a protein backbone or side chains. ASP-153 and ASP-245 are showing minimal ionic interaction with the ligand ([Figure 9](#F0009){ref-type="fig"}). *Water bridges* are hydrogen-bonded protein-ligand interactions mediated by a water molecule. The hydrogen-bond geometry is slightly relaxed from the standard hydrogen bond definition. The current geometric criteria for a protein-water or water-ligand hydrogen bonds are: a distance of 2.8 Å between the donor and acceptor atoms (D---H···A); a donor angle of ≥110° between the donor-hydrogen-acceptor atoms (D---H···A); and an acceptor angle of ≥90° between the hydrogen-acceptor-bonded_atom (H···A---X). Almost all the major interacting amino acids are showing water bridges ([Figure 9](#F0009){ref-type="fig"}). In this protein-ligand contact histograms some amino acids were showing highly effective interactions like 'ASP-153 and PHE-294' having 62% and 83% time interactions in **6LU7-CQD15** complex of 100 ns simulation.

![The histogram of protein-ligand contact over the course of the trajectory.](TBSD_A_1772111_F0009_C){#F0009}

A timeline representation of the interactions and contacts (Hydrogen bonds, Hydrophobic, Ionic and Water bridges) summarized in the ligand-receptor interaction (histogram) study analysed in the following two panels in [Figure 10(a, b)](#F0010){ref-type="fig"}. The top panel shows the total number of specific contacts the protein makes with the ligand in each and every trajectory frame. The number of contact varies zero to nine over the course of the trajectory ([Figure 10(a)](#F0010){ref-type="fig"}). The contribution of amino acids in each trajectory frame of 100 ns MD simulation was studied from ligand-protein interaction (bottom panel) ([Figure 10(b)](#F0010){ref-type="fig"}). The bottom panel shows, which amino acid residues interact with the ligand in each trajectory frame. Some residues make more than one specific contact with the ligand in a particular trajectory frame, which is represented by a darker shade of orange, according to the scale to the bellow the plot. The **6LU7-CQD15** receptor-ligand complex shows two deep bands **(**PHE-294 and ASP-153 row), which explains that the above amino acid have more interactions with the ligands in almost all possible orientations (geometry) which is exactly similar as histogram results.

![(a) Total number of contacts/interaction in each trajectory frame of **6LU7-CQD15** complex. (b) Interaction shown by the active site amino acids in each trajectory frame of **6LU7-CQD15** complex.](TBSD_A_1772111_F0010_C){#F0010}

Conclusion {#s0012}
==========

A series of computational approaches used to identify more effective drug candidate against SARS-CoV-2. The pharmacophore modelling, molecular docking, MM_GBSA study and ADME property analysis combinedly concluded with 3 ligands (**CQD15**, **CQD14** and **CQD16**) which have good docking score, ligand-receptor interactions, pharmacophore-based structural features and drug likeness property in comparison to chloroquine and hydroxychloroquine. The ligand-receptor MD simulation study validates the molecular docking study by exploring the protein stability (RMSD), various ligand property and protein-ligand contacts. Further, in vitro analysis followed by its in vivo testing may help in proving **CQD15** ligand as a better inhibitor of SARS-CoV-2. The whole study concludes that derivatives of chloroquine may play a prominent role for the treatment of COVID-19.
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